ArticleStem cell research & therapy2025
Human umbilical cord mesenchymal stem cells ameliorates cisplatin-induced blood-testis barrier dysfunction in mice by mitigating ferroptosis.
Article in Stem cell research & therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The impact of mesenchymal stromal cells on the proliferation and functional maturation of liver organoids.Biology direct · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundCisplatin (CDDP), a widely used chemotherapeutic agent, induces reproductive toxicity primarily by damaging the blood-testis barrier (BTB) and triggering oxidative stress. This study aimed to investigate whether human umbilical cord mesenchymal stem cells (hUC-MSCs) protect against CDDP-induced BTB dysfunction and ferroptosis in mice, with implications for preserving fertility in chemotherapy patients.
methodsMale C57 mice were randomized into four groups: control, CDDP-treated, hUC-MSCs-treated, and CDDP+hUC-MSCs-treated. An additional CDDP+Ferrostatin-1 (Fer-1, a ferroptosis inhibitor) group was included to validate ferroptosis involvement. Testicular histology, sperm quality, BTB integrity (via Evans blue permeability assay), and oxidative stress markers were evaluated. Ferroptosis-related (GPX4, NRF2, COX2, TFR1) and BTB-related (N-cadherin, ZO-1, Connexin 43) proteins were assessed by immunofluorescence and Western blotting. In vitro fertilization (IVF) was used to evaluate fertility.
resultsCDDP induced significant testicular damage, reduced sperm quality, increased BTB permeability, and disrupted BTB proteins. It also triggered ferroptosis, as evidenced by decreased GSH, elevated MDA, downregulated GPX4/NRF2, and upregulated COX2/TFR1. hUC-MSCs reversed these changes: restoring GSH levels, reducing MDA, normalizing ferroptosis-related proteins, and repairing BTB integrity. Fer-1 mimicked these effects, confirming ferroptosis as a key mechanism. IVF showed hUC-MSCs restored embryonic development (two-cell and blastocyst rates) to normal.
conclusionshUC-MSCs protect against CDDP-induced reproductive injury by inhibiting ferroptosis (especially in Sertoli cells), repairing BTB, and restoring fertility. Their transient retention and low immunogenicity support their potential as a safe therapeutic strategy for preserving fertility in chemotherapy patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.